[go: up one dir, main page]

PE20071310A1 - Formulaciones liquidas de fenilefrina - Google Patents

Formulaciones liquidas de fenilefrina

Info

Publication number
PE20071310A1
PE20071310A1 PE2007000185A PE2007000185A PE20071310A1 PE 20071310 A1 PE20071310 A1 PE 20071310A1 PE 2007000185 A PE2007000185 A PE 2007000185A PE 2007000185 A PE2007000185 A PE 2007000185A PE 20071310 A1 PE20071310 A1 PE 20071310A1
Authority
PE
Peru
Prior art keywords
composition
liquid
phenylephrine
glycerin
sorbitol
Prior art date
Application number
PE2007000185A
Other languages
English (en)
Inventor
William Bubnis
Stephanie Shield
Amanda Alley
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20071310A1 publication Critical patent/PE20071310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION ACUOSA ORAL QUE COMPRENDE: FENILEFRINA, ENDULZANTE ARTIFICIAL, HASTA 45% P/V DE GLICERINA, HASTA 10% P/V DE SORBITOL; DONDE LA PROPORCION DE GLICERINA A SORBITOL ESTA ENTRE 2:1 Y 10:1. EL ENDULZANTE ARTIFICIAL SE SELECCIONA DE SUCRALOSA, SALES DE SACARINA, CICLAMATOS, ACESULFAME DE POTASIO, ASPARTAME Y MEZCLA DE ELLOS. LA COMPOSICION PUEDE INCLUIR UN SEGUNDO COMPUESTO ACTIVO TAL COMO ACETAMINOFEN, DIFENHIDRAMINA, DEXTROMETORFANO, ENTRE OTROS; ASI COMO UN AGENTE PRESERVANTE TAL COMO BENZOATO DE SODIO, SORBATOS, PARABENOS, EDTA O MEZCLAS DE ELLOS; UN ANTIOXIDANTE TAL COMO GALATO DE PROPILO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL RESFRIADO
PE2007000185A 2006-02-21 2007-02-20 Formulaciones liquidas de fenilefrina PE20071310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77463406P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
PE20071310A1 true PE20071310A1 (es) 2007-12-12

Family

ID=38283964

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000185A PE20071310A1 (es) 2006-02-21 2007-02-20 Formulaciones liquidas de fenilefrina
PE2010001013A PE20110010A1 (es) 2006-02-21 2007-02-20 Formulaciones liquidas de fenilefrina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2010001013A PE20110010A1 (es) 2006-02-21 2007-02-20 Formulaciones liquidas de fenilefrina

Country Status (12)

Country Link
US (4) US8940796B2 (es)
EP (2) EP1986606B1 (es)
AU (1) AU2007217799B2 (es)
CA (1) CA2642048C (es)
ES (2) ES2692890T3 (es)
HU (2) HUE043620T2 (es)
PE (2) PE20071310A1 (es)
PL (2) PL1986606T3 (es)
PT (2) PT2316425T (es)
TR (2) TR201815803T4 (es)
TW (1) TWI482620B (es)
WO (1) WO2007098128A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
TWI411451B (zh) * 2006-06-01 2013-10-11 Msd Consumer Care Inc 用於結腸吸收之脫羥腎上腺素醫藥調配物及組合物
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
AR061166A1 (es) * 2006-06-01 2008-08-06 Schering Corp Composiciones farmaceuticas para la liberacion sostenida de fenilferina
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
WO2008150493A1 (en) * 2007-06-01 2008-12-11 Schering-Plough Healthcare Products, Inc. Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015137829A1 (en) * 2014-03-12 2015-09-17 Angeles Relinda G Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104983732B (zh) * 2015-05-28 2018-05-04 华润三九医药股份有限公司 一种布洛肾素那敏片及其制备方法
CN104922124B (zh) * 2015-05-28 2017-06-30 华润三九医药股份有限公司 一种肾素那敏片及其制备方法
US20210162051A1 (en) * 2018-07-09 2021-06-03 Olufoyekemi BADEJO Aqueous-based compositions
CN109125257B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚愈创肾素口服液及其制备方法
CN109045003B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚拉明肾素口服液及其制备方法
CN109044968B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚右美肾素口服液及其制备方法
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN110507607A (zh) * 2019-09-27 2019-11-29 葵花药业集团北京药物研究院有限公司 苯海拉明肾素口服液及其制备方法和用途
HRP20240108T1 (hr) 2019-12-23 2024-04-12 Nutra Essential Otc, S.L. Tekući sastav koji sadrži ibuprofen i fenilefrin
WO2021150747A1 (en) * 2020-01-22 2021-07-29 Nevakar Inc. Phenylephrine hydrochloride compositions and containers
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法
CN112076183A (zh) * 2020-08-28 2020-12-15 北京博达绿洲医药科技研究有限公司 包含盐酸去氧肾上腺素液体组合物
CN112402416A (zh) * 2020-12-18 2021-02-26 北京博达绿洲医药科技研究有限公司 一种治疗感冒的复方液体制剂及其制备方法
CN113081958B (zh) * 2021-05-01 2022-05-03 安徽新世纪药业有限公司 一种地氯雷他定口服溶液及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
AU670567B2 (en) 1992-03-05 1996-07-25 American Home Products Corporation Pharmaceutical coated cores
US5405604A (en) * 1992-10-16 1995-04-11 The Procter & Gamble Company Concentrated mouthrinse for efficient delivery of antimicrobials
AU3154895A (en) 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
PT1051155E (pt) * 1998-01-30 2002-10-31 Novartis Consumer Health Sa Solucoes nasais
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
EP1411955A4 (en) * 2001-07-31 2006-07-05 Wyeth Corp SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE
US6462094B1 (en) * 2001-08-22 2002-10-08 Medpointe Healthcare Inc. Decongestant/expectorant compositions
US6509492B1 (en) 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080234291A1 (en) * 2004-01-21 2008-09-25 Marc Karel Jozef Francois Mitratapide Oral Solution
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
AU2005315291A1 (en) 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositions and methods for stabilizing active pharmaceutical ingredients
US20070160689A1 (en) 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
CN101472561A (zh) 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物

Also Published As

Publication number Publication date
US20190209688A1 (en) 2019-07-11
PE20110010A1 (es) 2011-01-12
EP1986606A2 (en) 2008-11-05
EP2316425A1 (en) 2011-05-04
EP1986606B1 (en) 2019-04-10
TR201815803T4 (tr) 2018-11-21
TR201906970T4 (tr) 2019-06-21
TW200800143A (en) 2008-01-01
US9801941B2 (en) 2017-10-31
US11406712B2 (en) 2022-08-09
EP2316425B1 (en) 2018-08-29
US11419938B2 (en) 2022-08-23
AU2007217799B2 (en) 2012-12-13
PT1986606T (pt) 2019-06-12
WO2007098128A2 (en) 2007-08-30
US20070197661A1 (en) 2007-08-23
ES2728823T3 (es) 2019-10-28
US20170333561A1 (en) 2017-11-23
US8940796B2 (en) 2015-01-27
ES2692890T3 (es) 2018-12-05
CA2642048C (en) 2015-11-24
CA2642048A1 (en) 2007-08-30
TWI482620B (zh) 2015-05-01
PT2316425T (pt) 2018-11-13
US20150150976A1 (en) 2015-06-04
PL1986606T3 (pl) 2019-08-30
WO2007098128A3 (en) 2007-10-11
AU2007217799A1 (en) 2007-08-30
HUE039382T2 (hu) 2018-12-28
HUE043620T2 (hu) 2019-08-28
PL2316425T3 (pl) 2019-01-31

Similar Documents

Publication Publication Date Title
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
AR117718A2 (es) Mejoramientos en composiciones farmacéuticas, y relacionados con ellas
UY27320A1 (es) Nuevas composiciones farmacéuticas
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
AR053737A1 (es) Formulacion pediatrica de topiramato
ES2570599T3 (es) Composición suave para desinfección cutánea
PE20081114A1 (es) Composiciones farmaceuticas bioadhesivas de agente dual para uso topico
TW200733968A (en) Stabilized lanthanum carbonate compositions
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
RU2013134257A (ru) Водная композиция для ухода за полостью рта, включающая ксантановую камедь, целлюлозную камедь и карбомер
CO6220902A2 (es) Formulacion en polvo del valganciclovir
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
HRP20020404B1 (hr) Otopine koje sadrže epinastin
PE20040321A1 (es) Composicion topica que comprende diclofenaco
MX2007011039A (es) Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.
SE9903831D0 (sv) Formulation of substituted benzimidazoles
ITTO20120776A1 (it) Procedimento per mascherare l'amaro di un filtro uv
PE20060364A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
DK1843754T3 (da) Ny farmaceutisk sammensætning indeholdende candesartan-cilexetil som lipofilt krystallinsk stof
JP6336334B2 (ja) 液体洗浄剤組成物
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador

Legal Events

Date Code Title Description
FC Refusal